Sitemap > News > Pain
Displaying 1 - 50 of 660 results
- Progenics and Wyeth Announce FDA Has Accepted for Filing the New Drug Application for Subcutaneous Methylnaltrexone
- Valeant Pharmaceuticals to Initiate Study of Retigabine for Pain Associated with Post-Herpetic Neuralgia
- ROXRO PHARMA’s novel intranasal pain reliever effective, well tolerated in phase 3 study
- NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting
- AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
- FROVA Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
- Penwest Begins Dosing Phase IIa Clinical Study of Nalbuphine ER
- WEX Receives No Objection Letter from Health Canada for Phase III Clinical Trial in Cancer Pain
- DEPOMED INITIATES DOSING OF PATIENTS IN PHASE 2 TRIAL FOR GABAPENTIN GR FOR THE TREATMENT OF MENOPAUSAL HOT FLASHES
- Prexige® study shows significantly less impact on blood pressure than ibuprofen in osteoarthritis patients with controlled hypertension
- Acura Pharmaceuticals, Inc. and FDA Reach Agreement on Special Protocol Assessment for Pivotal Phase 3 Study for OxyADF Tablets
- Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
- Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review
- YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF
- DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
- Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
- CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
- Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of QUADRAMET(R) at International Myeloma Workshop
- NicOx initiates third pivotal naproxcinod phase 3 study
- Newron Reports Positive Phase Ii Results For Ralfinamide In Neuropathic Pain
- Labopharm meets with FDA to discuss second Approvable Letter for once-daily tramadol
- Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
- BEMA Fentanyl NDA Submission Remains on Target for Third Quarter Following Meeting With FDA
- DEPOMED ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIAL FOR GABAPENTIN GR(TM) IN POSTHERPETIC NEURALGIA
- Patient Recruitment Completed for Pivotal Phase III Study of Remoxy
- Collegium Pharmaceutical Inc. Announces FDA Acceptance of IND for its Abuse Deterrent Sustained Release Opioid Product
- YM BIOSCIENCES ANNOUNCES SECONDARY EFFICACY AND SAFETY FINDINGS IN RANDOMIZED PHASE IIB AEROLEF™ TRIAL
- DURECT Reports Positive Results from POSIDUR Phase IIb Hernia Trial, Triggering $8 million Milestone Payment from Nycomed
- Wyeth and Progenics Announce Positive Preliminary Results of Phase 1 Study of New Oral Formulation of Methylnaltrexone
- EpiCept Announces Phase III Study of EpiCept NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- AKELA PHARMA INC. COMPLETES PATIENT ENROLLMENT IN ITS FENTANYL TAIFUN® PHASE IIB TRIAL
- Javelin Pharmaceuticals Begins Second Phase 3 Study of Dyloject
- Javelin Pharmaceuticals Begins Second Phase 3 Study of Dyloject
- Javelin Pharmaceuticals Initiates Phase 3 Breakthrough Cancer Pain Trial for Intranasal Ketamine
- FDA issues second approvable letter for Trexima
- TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
- Metabolic discontinues clinical trial programme for neuropathic pain drug, ACV1
- NeurAxon Announces Positive Phase 1 Trial Data on NXN-188 for Migraine
- Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
- Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
- New Data Suggest Cymbalta® Reduced Pain in Fibromyalgia Patients With and Without Depression
- Cannasat Therapeutics to Commence Phase 1 Study of CAT 310, a Potential Treatment for Neuropathic Pain
- DIAMYD UPDATES GENE THERAPY PROGRAM AND OUTLINES PLANS FOR PHASE I CLINICAL TRIAL FOR TREATMENT OF CANCER PAIN
- TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
- Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
- Biovail Receives Canadian Approval for Ralivia
- NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
- AKELA PHARMA INC. ANNOUNCES POSITIVE RESULTS FOR THE EXTENSION PART OF ITS PHASE IIB FENTANYL TAIFUN® TRIAL
- XTL BIOPHARMACEUTICALS INITIATES PHASE IIB CLINICAL TRIAL OF BICIFADINE FOR THE TREATMENT OF DIABETIC NEUROPATHIC PAIN
- Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol)